These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

152 related items for PubMed ID: 20570147

  • 1. Reducing ion channel activity in a series of 4-heterocyclic arylamide FMS inhibitors.
    Wilson KJ, Illig CR, Chen J, Wall MJ, Ballentine SK, DesJarlais RL, Chen Y, Schubert C, Donatelli R, Petrounia I, Crysler CS, Molloy CJ, Chaikin MA, Manthey CL, Player MR, Tomczuk BE, Meegalla SK.
    Bioorg Med Chem Lett; 2010 Jul 01; 20(13):3925-9. PubMed ID: 20570147
    [Abstract] [Full Text] [Related]

  • 2. Enhancement of kinase selectivity in a potent class of arylamide FMS inhibitors.
    Illig CR, Manthey CL, Meegalla SK, Wall MJ, Chen J, Wilson KJ, DesJarlais RL, Ballentine SK, Schubert C, Crysler CS, Chen Y, Molloy CJ, Chaikin MA, Donatelli RR, Yurkow E, Zhou Z, Player MR, Tomczuk BE.
    Bioorg Med Chem Lett; 2013 Dec 01; 23(23):6363-9. PubMed ID: 24138939
    [Abstract] [Full Text] [Related]

  • 3. 3-amido-4-anilinocinnolines as a novel class of CSF-1R inhibitor.
    Scott DA, Dakin LA, Del Valle DJ, Diebold RB, Drew L, Gero TW, Ogoe CA, Omer CA, Repik G, Thakur K, Ye Q, Zheng X.
    Bioorg Med Chem Lett; 2011 Mar 01; 21(5):1382-4. PubMed ID: 21295474
    [Abstract] [Full Text] [Related]

  • 4. Structure-based optimization of a potent class of arylamide FMS inhibitors.
    Meegalla SK, Wall MJ, Chen J, Wilson KJ, Ballentine SK, Desjarlais RL, Schubert C, Crysler CS, Chen Y, Molloy CJ, Chaikin MA, Manthey CL, Player MR, Tomczuk BE, Illig CR.
    Bioorg Med Chem Lett; 2008 Jun 15; 18(12):3632-7. PubMed ID: 18495479
    [Abstract] [Full Text] [Related]

  • 5. The discovery and initial optimisation of pyrrole-2-carboxamides as inhibitors of p38alpha MAP kinase.
    Down K, Bamborough P, Alder C, Campbell A, Christopher JA, Gerelle M, Ludbrook S, Mallett D, Mellor G, Miller DD, Pearson R, Ray K, Solanke Y, Somers D.
    Bioorg Med Chem Lett; 2010 Jul 01; 20(13):3936-40. PubMed ID: 20570148
    [Abstract] [Full Text] [Related]

  • 6. Design and synthesis of 5,6-fused heterocyclic amides as Raf kinase inhibitors.
    Ramurthy S, Aikawa M, Amiri P, Costales A, Hashash A, Jansen JM, Lin S, Ma S, Renhowe PA, Shafer CM, Subramanian S, Sung L, Verhagen J.
    Bioorg Med Chem Lett; 2011 Jun 01; 21(11):3286-9. PubMed ID: 21543226
    [Abstract] [Full Text] [Related]

  • 7. Discovery of novel FMS kinase inhibitors as anti-inflammatory agents.
    Illig CR, Chen J, Wall MJ, Wilson KJ, Ballentine SK, Rudolph MJ, DesJarlais RL, Chen Y, Schubert C, Petrounia I, Crysler CS, Molloy CJ, Chaikin MA, Manthey CL, Player MR, Tomczuk BE, Meegalla SK.
    Bioorg Med Chem Lett; 2008 Mar 01; 18(5):1642-8. PubMed ID: 18242992
    [Abstract] [Full Text] [Related]

  • 8. Pyrido[2,3-d]pyrimidin-5-ones: a novel class of antiinflammatory macrophage colony-stimulating factor-1 receptor inhibitors.
    Huang H, Hutta DA, Rinker JM, Hu H, Parsons WH, Schubert C, DesJarlais RL, Crysler CS, Chaikin MA, Donatelli RR, Chen Y, Cheng D, Zhou Z, Yurkow E, Manthey CL, Player MR.
    J Med Chem; 2009 Feb 26; 52(4):1081-99. PubMed ID: 19193011
    [Abstract] [Full Text] [Related]

  • 9. Discovery of 2-(alpha-methylbenzylamino) pyrazines as potent Type II inhibitors of FMS.
    Burns CJ, Harte MF, Bu X, Fantino E, Giarrusso M, Joffe M, Kurek M, Legge FS, Razzino P, Su S, Treutlein H, Wan SS, Zeng J, Wilks AF.
    Bioorg Med Chem Lett; 2009 Feb 15; 19(4):1206-9. PubMed ID: 19128971
    [Abstract] [Full Text] [Related]

  • 10. Synthesis and evaluation of novel 3,4,6-substituted 2-quinolones as FMS kinase inhibitors.
    Wall MJ, Chen J, Meegalla S, Ballentine SK, Wilson KJ, DesJarlais RL, Schubert C, Chaikin MA, Crysler C, Petrounia IP, Donatelli RR, Yurkow EJ, Boczon L, Mazzulla M, Player MR, Patch RJ, Manthey CL, Molloy C, Tomczuk B, Illig CR.
    Bioorg Med Chem Lett; 2008 Mar 15; 18(6):2097-102. PubMed ID: 18289848
    [Abstract] [Full Text] [Related]

  • 11. Structure-guided design of aminopyrimidine amides as potent, selective inhibitors of lymphocyte specific kinase: synthesis, structure-activity relationships, and inhibition of in vivo T cell activation.
    DiMauro EF, Newcomb J, Nunes JJ, Bemis JE, Boucher C, Chai L, Chaffee SC, Deak HL, Epstein LF, Faust T, Gallant P, Gore A, Gu Y, Henkle B, Hsieh F, Huang X, Kim JL, Lee JH, Martin MW, McGowan DC, Metz D, Mohn D, Morgenstern KA, Oliveira-dos-Santos A, Patel VF, Powers D, Rose PE, Schneider S, Tomlinson SA, Tudor YY, Turci SM, Welcher AA, Zhao H, Zhu L, Zhu X.
    J Med Chem; 2008 Mar 27; 51(6):1681-94. PubMed ID: 18321037
    [Abstract] [Full Text] [Related]

  • 12. Synthesis, biological evaluation and molecular docking studies of amide-coupled benzoic nitrogen mustard derivatives as potential antitumor agents.
    Zheng QZ, Zhang F, Cheng K, Yang Y, Chen Y, Qian Y, Zhang HJ, Li HQ, Zhou CF, An SQ, Jiao QC, Zhu HL.
    Bioorg Med Chem; 2010 Jan 15; 18(2):880-6. PubMed ID: 20005116
    [Abstract] [Full Text] [Related]

  • 13. Rapid preparation of triazolyl substituted NH-heterocyclic kinase inhibitors via one-pot Sonogashira coupling-TMS-deprotection-CuAAC sequence.
    Merkul E, Klukas F, Dorsch D, Grädler U, Greiner HE, Müller TJ.
    Org Biomol Chem; 2011 Jul 21; 9(14):5129-36. PubMed ID: 21625704
    [Abstract] [Full Text] [Related]

  • 14. Design and synthesis of 6,6-fused heterocyclic amides as raf kinase inhibitors.
    Ramurthy S, Costales A, Jansen JM, Levine B, Renhowe PA, Shafer CM, Subramanian S.
    Bioorg Med Chem Lett; 2012 Feb 15; 22(4):1678-81. PubMed ID: 22264479
    [Abstract] [Full Text] [Related]

  • 15. Identification of 2-acylaminothiophene-3-carboxamides as potent inhibitors of FLT3.
    Patch RJ, Baumann CA, Liu J, Gibbs AC, Ott H, Lattanze J, Player MR.
    Bioorg Med Chem Lett; 2006 Jun 15; 16(12):3282-6. PubMed ID: 16580199
    [Abstract] [Full Text] [Related]

  • 16. Piperidine-based heterocyclic oxalyl amides as potent p38 alpha MAP kinase inhibitors.
    Mavunkel BJ, Perumattam JJ, Tan X, Luedtke GR, Lu Q, Lim D, Kizer D, Dugar S, Chakravarty S, Xu YJ, Jung J, Liclican A, Levy DE, Tabora J.
    Bioorg Med Chem Lett; 2010 Feb 01; 20(3):1059-62. PubMed ID: 20031411
    [Abstract] [Full Text] [Related]

  • 17. Lead optimization and structure-based design of potent and bioavailable deoxycytidine kinase inhibitors.
    Jessop TC, Tarver JE, Carlsen M, Xu A, Healy JP, Heim-Riether A, Fu Q, Taylor JA, Augeri DJ, Shen M, Stouch TR, Swanson RV, Tari LW, Hunter M, Hoffman I, Keyes PE, Yu XC, Miranda M, Liu Q, Swaffield JC, David Kimball S, Nouraldeen A, Wilson AG, Foushee AM, Jhaver K, Finch R, Anderson S, Oravecz T, Carson KG.
    Bioorg Med Chem Lett; 2009 Dec 01; 19(23):6784-7. PubMed ID: 19836232
    [Abstract] [Full Text] [Related]

  • 18. High-content screening of feeder-free human embryonic stem cells to identify pro-survival small molecules.
    Andrews PD, Becroft M, Aspegren A, Gilmour J, James MJ, McRae S, Kime R, Allcock RW, Abraham A, Jiang Z, Strehl R, Mountford JC, Milligan G, Houslay MD, Adams DR, Frearson JA.
    Biochem J; 2010 Nov 15; 432(1):21-33. PubMed ID: 20854259
    [Abstract] [Full Text] [Related]

  • 19. Discovery of a new potent bisamide FMS kinase inhibitor.
    El-Gamal MI, Jung MH, Oh CH.
    Bioorg Med Chem Lett; 2010 Jun 01; 20(11):3216-8. PubMed ID: 20457522
    [Abstract] [Full Text] [Related]

  • 20. Discovery of pyrimidine carboxamides as potent and selective CCK1 receptor agonists.
    Wang L, Hubert JA, Lee SJ, Pan J, Qian S, Reitman ML, Strack AM, Weingarth DT, MacNeil DJ, Weber AE, Edmondson SD.
    Bioorg Med Chem Lett; 2011 May 15; 21(10):2911-5. PubMed ID: 21493064
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.